Is tetrabenazine safe and effective for suppressing chorea in Huntington's disease?

Nature Clinical Practice Neurology

Volumn 2, Issue 10, 2006, Pages 536-537

  Leavitt, Blair R ^a   Hayden, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; PLACEBO; TETRABENAZINE;

AKATHISIA; BRADYKINESIA; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DISEASE EXACERBATION; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FALLING; HUMAN; HUNTINGTON CHOREA; INSOMNIA; MOOD DISORDER; MUSCLE RIGIDITY; OUTCOMES RESEARCH; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZATION; RESTLESSNESS; SCORING SYSTEM; SEDATION; SHORT SURVEY; SIDE EFFECT; SUICIDAL IDEATION; SUICIDE; TARDIVE DYSKINESIA;

EID: 33749014397     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0299     Document Type: Short Survey

References (5)

1. Leavitt BR and Hayden MR (2000) Huntington's disease. In Kelley's Textbook of Internal Medicine, edn 4, 2926-2928 (Ed. Humes HD) Philadelphia: Lippincott Williams and Wilkins
2. Frank S et al. (2004) Functional decline due to chorea in Huntington's disease. Neurology 62: A204
3. Grimbergen YAM and Roos RAC (2003) Therapeutic options for Huntington's disease. Curr Opin Invest Drugs 4: 51-54
4. Barr AN et al. (1988) Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology 38: 84-88
5. Kenney C and Jankovic J (2006) Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 6: 7-17